NCT02506023

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: Female
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).

Detailed description

DDAVP (Desmopressin) is commonly used in the treatment of persons with bleeding disorders such as hemophilia, von Willebrand disease, or qualitative platelet disorders to help them clot better. The investigator wants to assess the increase in the subjects' clotting factors in response to intravenous DDAVP (Desmopressin) and the levels of these internal clotting factors will be measured at different times after the medication is given. The investigator will compare the response to DDAVP (Desmopressin) in adult hemophilia A carriers to women with a diagnosis of qualitative platelet dysfunction.

Conditions

• Hemophilia A

Interventions

Type	Name	Description
DRUG	Desmopressin	Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.

Timeline

• Start date: 2015-07-01
• Primary completion: 2018-06-15
• Completion: 2018-06-15
• First posted: 2015-07-22
• Last updated: 2018-07-16

Locations

2 sites across 1 country: United States